# Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

> **NCT02124746** · PHASE2 · COMPLETED · sponsor: **Sierra Oncology LLC - a GSK company** · enrollment: 87 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Post-Essential Thrombocythemia Myelofibrosis
- Polycythemia Vera
- Essential Thrombocythemia

## Interventions

- **DRUG:** Momelotinib

## Key facts

- **NCT ID:** NCT02124746
- **Lead sponsor:** Sierra Oncology LLC - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-30
- **Primary completion:** 2018-12-06
- **Final completion:** 2018-12-06
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02124746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02124746, "Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02124746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*